tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Lexaria Bioscience Strengthens GLP-1 Drug Delivery Focus and Expands Patent Portfolio in 2024

Story Highlights
Lexaria Bioscience Strengthens GLP-1 Drug Delivery Focus and Expands Patent Portfolio in 2024

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Lexaria Bioscience ( (LEXX) ) has shared an announcement.

In 2024, Lexaria Bioscience Corp. made significant strides by focusing on GLP-1 drug delivery, achieving promising results from multiple human and animal studies, which highlight the potential of their DehydraTECH technology. The company successfully raised $13.4 million to support its operations and development plans, launched its first Phase 1b study in Australia, received FDA clearance for a hypertension study, and expanded its patent portfolio with eight new patents, reflecting its strengthened position in the pharmaceutical industry.

More about Lexaria Bioscience

Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, focusing primarily on developing oral-based drug delivery technologies. The company is leveraging its proprietary DehydraTECH technology to target the growing GLP-1 drug sector, which is one of the largest and fastest-growing in the world.

YTD Price Performance: -21.30%

Average Trading Volume: 198,671

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $30.01M

See more insights into LEXX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1